OI Sciences

June 08: South West of England Press Release for Launch of OI Sciences.
May 08: OI Sciences launches Amiodarone ampoules in the UK.
April 08: OI Sciences launches Fluconazole Solution for Infusion with new
ml size for paediatrics in the UK
April 08: OI Sciences Board of Directors is established and first Board
Meeting is held.
April 08: OI Sciences is successfully spun out from Opal Healthcare and
becomes fully operational.
Sept 06: Opal Healthcare moves premises to the South West of the UK

OI Sciences is delighted to have achieved the Marketing Authorisation for Amiodarone solution for IV injection in ampoules in Feb 08.

The Company has successfully secured three NHS contracts for England, Scotland and Wales.

OI Sciences is delighted to have achieved the Marketing Authorisation for Fluconazole Solution for Infusion in the UK and launched the product for sale in April 08. OI Sciences offers a new intermediate ml size for paediatric hospitals and it will assist physicians, pharmacists and patients in the management of fungal infections. The company has successfully secured a NHS contract for the new ml size.

Opal Healthcare Limited moves premises to the South West of the UK.

“This is a significant move for Opal Healthcare developing the business into its next phase. The business is growing rapidly and expanding the premises and achieving the next phase of investment is paramount in ensuring that Opal Healthcare increases its present portfolio of products to 12 -15 within the next 24 months. The delightful premises offer an excellent working environment for the employees where a work life balance can be achieved. The South West region is developing fast and Opal Healthcare hopes to capitalize on building relationships here with local medical and healthcare companies”
Yasmin Crawford, Managing Director